News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Great news!  This is one of my favorite experimental treatments.  Fast track designation will speed up the approval process!

 


Posted on: 12/26/2017

DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740